Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

Abstract

BACKGROUNDIt is unclear whether patients with early-stage Hodgkin's lymphoma and negative findings on positron-emission tomography (PET) after three cycles of chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) require radiotherapy. METHODSPatients with newly diagnosed stage IA or stage IIA Hodgkin's lymphoma received three cycles of ABVD and then underwent PET scanning. Patients with negative PET findings were randomly assigned to receive involved-field radiotherapy or no further treatment; patients with positive PET findings received a fourth cycle of ABVD and radiotherapy. This trial assessing the noninferiority of no further treatment was designed to exclude a difference in the 3-year progression-free survival rate of 7 or more percentage points from the assumed 95% progression-free survival rate in the radiotherapy group. RESULTSA total of 602 patients (53.3% male; median age, 34 years) were recruited, and 571 patients underwent PET scanning. The PET findings were negative in 426 of these patients (74.6%), 420 of whom were randomly assigned to a study group (209 to the radiotherapy group and 211 to no further therapy). At a median of 60 months of follow-up, there had been 8 instances of disease progression in the radiotherapy group, and 8 patients had died (3 with disease progression, 1 of whom died from Hodgkin's lymphoma); there had been 20 instances of disease progression in the group with no further therapy, and 4 patients had died (2 with disease progression and none from Hodgkin's lymphoma). In the radiotherapy group, 5 of the deaths occurred in patients who received no radiotherapy. The 3-year progression-free survival rate was 94.6% (95% confidence interval [CI], 91.5 to 97.7) in the radiotherapy group and 90.8% (95% CI, 86.9 to 94.8) in the group that received no further therapy, with an absolute risk difference of −3.8 percentage points (95% CI, −8.8 to 1.3). CONCLUSIONSThe results of this study did not show the noninferiority of the strategy of no further treatment after chemotherapy with regard to progression-free survival. Nevertheless, patients in this study with early-stage Hodgkin's lymphoma and negative PET findings after three cycles of ABVD had a very good prognosis either with or without consolidation radiotherapy. Original ArticleThe New England Journal of Medicine also emerged. Thus, it was increasingly apparent that cure was bought at a high price and that less damaging therapies were required. Studies were therefore performed to evaluate fewer cycles of less toxic chemotherapy combined with smaller fields or doses of radiotherapy 13,14 ; as a result, for the treatment of patients with favorable prognostic features, 14,15 two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) 16,17 followed by 20 Gy of involved-field radiotherapy is now commonly used. 15In moving toward the goal of maximizing cure while minimizing toxic effects, greater individualization of therapy is appealing. Positron-emission tomography (PET) can be used to predict the...

FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?

“…The UK RAPID study 8 and the EORTC H10 study 9 have randomized patients with complete metabolic response (CMR) on iPET after 2-4 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) treatment to receive radiotherapy (RT) or no further treatment (NFT). Both were non-inferiority studies, with a slightly different design.…”

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

“…Interim PET scans may be useful to identify a subgroup of patients with early-stage disease that can be treated with chemotherapy alone. 21 The NCCN Guidelines emphasize that the value of interim PET scans remains unclear for many clinical scenarios and that all measures of response should be considered in the context of management decisions. It is important that the Deauville score be incorporated into the nuclear medicine PET scan report, because subsequent management often depends on that score.…”

Recent treatment advances in Hodgkin lymphoma: a concise review

“…Results of interim PET/CT appear to correlate well with long-term outcome following treatment with ABVD 28 . In early stage disease, PET/CT-adapted therapy was trialled in the recently completed RAPID UK study 29 , with the aim of establishing non-inferiority of treatment de-escalation based on interim PET/CT performed after three cycles of ABVD. Patients with interim PET/CT-negative scans (426 of the 571 patients studied) were randomised to receive either standard radiotherapy or no further treatment (i.e.…”